CY1111552T1 - Χρηση hpv16 και hpv18 ως εμβολιο εναντι ενος ή περισσοτερων ογκογονικου hpv τυπου 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 - Google Patents

Χρηση hpv16 και hpv18 ως εμβολιο εναντι ενος ή περισσοτερων ογκογονικου hpv τυπου 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Info

Publication number
CY1111552T1
CY1111552T1 CY20111100549T CY111100549T CY1111552T1 CY 1111552 T1 CY1111552 T1 CY 1111552T1 CY 20111100549 T CY20111100549 T CY 20111100549T CY 111100549 T CY111100549 T CY 111100549T CY 1111552 T1 CY1111552 T1 CY 1111552T1
Authority
CY
Cyprus
Prior art keywords
ovogenic
hpv18
hpv16
vaccine against
hpv type
Prior art date
Application number
CY20111100549T
Other languages
Greek (el)
English (en)
Inventor
Gary Dubin
Bruce Innis
Moncef M Slaoui
Mac Wettendorff
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1111552T1 publication Critical patent/CY1111552T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20111100549T 2002-12-20 2011-06-08 Χρηση hpv16 και hpv18 ως εμβολιο εναντι ενος ή περισσοτερων ογκογονικου hpv τυπου 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 CY1111552T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20
EP03789346A EP1572233B1 (en) 2002-12-20 2003-12-18 Use of HPV16 and HPV18 as vaccine against one or more of oncogenic HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Publications (1)

Publication Number Publication Date
CY1111552T1 true CY1111552T1 (el) 2015-08-05

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100549T CY1111552T1 (el) 2002-12-20 2011-06-08 Χρηση hpv16 και hpv18 ως εμβολιο εναντι ενος ή περισσοτερων ογκογονικου hpv τυπου 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Country Status (28)

Country Link
US (2) US20060251676A1 (enExample)
EP (1) EP1572233B1 (enExample)
JP (1) JP5475939B2 (enExample)
KR (3) KR20120118087A (enExample)
AP (1) AP2005003347A0 (enExample)
AR (1) AR042530A1 (enExample)
AT (1) ATE503492T1 (enExample)
AU (1) AU2003293942B2 (enExample)
BE (3) BE2015C068I2 (enExample)
BR (1) BR0317544A (enExample)
CA (1) CA2510457C (enExample)
CY (1) CY1111552T1 (enExample)
DE (1) DE60336581D1 (enExample)
DK (1) DK1572233T3 (enExample)
EA (2) EA200701633A1 (enExample)
EC (1) ECSP055869A (enExample)
IL (1) IL169085A (enExample)
IS (1) IS2811B (enExample)
MA (1) MA27581A1 (enExample)
MX (1) MXPA05006764A (enExample)
MY (1) MY144492A (enExample)
NO (1) NO20052846L (enExample)
NZ (1) NZ540811A (enExample)
OA (1) OA13147A (enExample)
PL (1) PL215257B1 (enExample)
PT (1) PT1572233E (enExample)
TW (1) TWI349557B (enExample)
WO (1) WO2004056389A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
KR20070029254A (ko) * 2004-06-16 2007-03-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
AR054259A1 (es) * 2005-04-26 2007-06-13 Glaxosmithkline Biolog Sa Vacuna contra virus de papiloma humano (hpv)
MX2007013475A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
EP2154147B1 (en) * 2007-04-29 2015-10-07 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. A truncated l1 protein of human papillomavirus 16
EP2147926B1 (en) 2007-04-29 2016-08-24 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
WO2010099580A1 (en) * 2009-03-05 2010-09-10 Jenny Colleen Mccloskey Treatment of infection
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
CA2965498A1 (en) 2014-10-24 2016-04-28 Hpvvax, Llc. Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
CA2987864C (en) * 2015-06-02 2020-08-18 Terumo Kabushiki Kaisha Adjuvant composition containing aluminum and vaccine composition containing the same
CN122399006A (zh) 2016-02-27 2026-07-17 哈普威克斯有限责任公司 使用疫苗治疗癌症或皮肤病变的方法和组合物
SG11202008539YA (en) * 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
BR112020024699A2 (pt) * 2018-06-04 2021-03-09 Xiamen University Mutante da proteína l1 do papilomavírus humano tipo 18
CA3121247A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
AU742409B2 (en) 1997-09-05 2002-01-03 Medimmune, Llc In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
ATE413188T1 (de) * 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
KR100919266B1 (ko) * 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법

Also Published As

Publication number Publication date
MA27581A1 (fr) 2005-10-03
TW200423957A (en) 2004-11-16
BE2015C068I2 (enExample) 2024-08-08
AR042530A1 (es) 2005-06-22
NZ540811A (en) 2007-03-30
IL169085A (en) 2014-04-30
DK1572233T3 (da) 2011-06-27
EA200500834A1 (ru) 2006-02-24
EA009179B1 (ru) 2007-12-28
IL169085A0 (en) 2007-07-04
JP5475939B2 (ja) 2014-04-16
BE2015C067I2 (enExample) 2024-08-08
ATE503492T1 (de) 2011-04-15
TWI349557B (en) 2011-10-01
OA13147A (en) 2006-12-13
IS7885A (is) 2005-06-09
AP2005003347A0 (en) 2005-06-30
KR20120118087A (ko) 2012-10-25
ECSP055869A (es) 2005-09-20
PL377710A1 (pl) 2006-02-06
DE60336581D1 (de) 2011-05-12
CA2510457A1 (en) 2004-07-08
US20050287161A1 (en) 2005-12-29
EA200701633A1 (ru) 2007-12-28
NO20052846L (no) 2005-07-13
EP1572233B1 (en) 2011-03-30
US20060251676A1 (en) 2006-11-09
CA2510457C (en) 2011-12-06
WO2004056389A1 (en) 2004-07-08
EP1572233A1 (en) 2005-09-14
HK1085378A1 (en) 2006-08-25
MY144492A (en) 2011-09-30
JP2006512413A (ja) 2006-04-13
MXPA05006764A (es) 2005-09-08
IS2811B (is) 2012-11-15
BE2015C069I2 (enExample) 2024-08-08
PT1572233E (pt) 2011-06-07
AU2003293942A1 (en) 2004-07-14
AU2003293942B2 (en) 2009-12-10
BR0317544A (pt) 2005-11-22
KR20120123616A (ko) 2012-11-08
KR101361769B1 (ko) 2014-02-10
PL215257B1 (pl) 2013-11-29
KR20050086924A (ko) 2005-08-30

Similar Documents

Publication Publication Date Title
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
ECSP045300A (es) Antígenos virales
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
NO20091976L (no) Nye forbindelser
DK1296711T3 (da) HPV-E7 til behandling af humant papillomavirus
CY1106682T1 (el) Ενωση λακταμης
LTC1758609I2 (lt) Vakcina prieš HPV16 ir HPV18 ir mažiausiai vieną kitą HVP tipą, parinktą iš HVP 31,45 arba 52
CY1112614T1 (el) Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης
CY1111521T1 (el) Λοιμογονος συστηματικος καλυκοϊος αιλουροειδων
JOP20220187A1 (ar) لقاح فيروس الورم الحليمي البشري (hpv)
EP1230932A3 (de) Verwendung von Antikörpern zur Vakzinierung gegen Krebs
AR047581A1 (es) Vacunas de calicivirus felino
NO20070195L (no) Vaksine mot HPV16 og HPV18 og minst en annen HPV-type valgt fra HPV31, 45 eller 52
EA200301151A1 (ru) Вакцина против натуральной оспы
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
CL2010001175A1 (es) Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
ATE437656T1 (de) Impfstoff gegen das maul- und klauensäure-virus
DE60305279D1 (de) Verwendung von Methyltestosteron zur Behandlung von menschlichen Papillomavirus Infektionen
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105345T1 (el) Φαινυλαλκινια
RU2002125322A (ru) 5(6)-нитро-1-(1,1-диоксотиетанил-3)-2-хлорбензимидазол, проявляющий биологическую активность
MY191101A (en) Protein from photobacterium damselae and use thereof
CY2015049I2 (el) Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
DE60238554D1 (de) Vakzine gegen infektionskrankheiten
EA200702077A1 (ru) Вакцина